Description: C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.
Home Page: www.c4xdiscovery.com
C4XD Technical Analysis
Manchester One
Manchester,
M1 3LD
United Kingdom
Phone:
44 1612 355 085
Officers
| Name | Title |
|---|---|
| Dr. Clive James Dix B.Sc., Ph.D. | CEO & Director |
| Mr. Bradley Richard Hoy | CFO, Sec. & Director |
| Ms. Emma Blaney Ph.D. | Chief Operating Officer |
| Ms. Bhavna Hunjan | Chief Bus. Officer & Director |
| Dr. Nick Ray Ph.D. | Sr. VP of Drug Discovery |
| Ms. Clare Murray Ph.D. | Sr. VP of Drug Discovery |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Technology |
| GIC Sub-Industry: | Health Care Technology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.5683 |
| Price-to-Sales TTM: | 20.3265 |
| IPO Date: | |
| Fiscal Year End: | July |
| Full Time Employees: | 48 |